Article Text

other Versions

Download PDFPDF
Protective effects of Helicobacter pylori for IBD are related to the cagA-positive strain
  1. A R Lord1,
  2. L A Simms1,
  3. K Hanigan1,
  4. R Sullivan2,
  5. P Hobson3,
  6. G L Radford-Smith1,4,5
  1. 1Inflammatory Bowel Diseases, QIMR Berghofer Medical Research Institute, Brisbane, Australia
  2. 2Abacus ALS, Auckland, New Zealand
  3. 3Immunology/Serology, Sullivan Nicolaides Pathology, Brisbane, Australia
  4. 4Department of Gastroenterology, Royal Brisbane and Women's Hospital, Brisbane, Australia
  5. 5University of Queensland School of Medicine, Herston Campus, Brisbane, Australia
  1. Correspondence to Dr G L Radford-Smith, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, Qld. 4006, Australia; graham.radford-smith{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the article by Castaño-Rodríguez et al,1 describing the role of Helicobacter pylori and Campylobacter spp in inflammatory bowel disease (IBD). While H. pylori infection has been shown to be protective against IBD, there is some ambiguity about the biological underpinnings of this effect. There is a spectrum of H pylori exposure across Caucasian populations with lower rates identified in Australian and USA studies.2 Importantly, Australia and other ‘new world’ regions such as the USA currently have some of the highest published incidence and prevalence rates for IBD.3–5

Multiple strains of H. pylori are observed, most notably, those with an active cytotoxin-associated gene A (cagA) and those without. The prevalence of the cagA gene in H. pylori is reported to be between 60% and 100% in western and eastern populations, respectively,6 potentially confounding any analysis on the …

View Full Text


  • Contributors Study was designed and clinical participants were recruited by GLR-S. Assay and technical expertise provided by RS. Data were collected by PH. Control participants were recruited by KH. Analysis was performed by ARL and LAS. Manuscript was written by ARL, LAS and GLR-S. Figures were created by ARL. Manuscript was reviewed by all authors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles